The aim of this review is to illustrate the main pathogenetic mechanisms by which the immune system promotes the progression of MASLD and the transition to HCC and to discuss the possible therapeutic applications of PD-1/PD-L1 target therapy. Here, PDCD1 is linked to metabolic dysfunction-associated steatotic liver disease.